Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute, School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan, Australia.
Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute, School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan, Australia
Eur Respir J. 2021 Mar 4;57(3). doi: 10.1183/13993003.00612-2020. Print 2021 Mar.
Obesity is a common comorbidity in asthma and associated with poorer asthma control, more frequent/severe exacerbations, and reduced response to asthma pharmacotherapy.
This review aims to compare use of all classes of asthma medications in obese (body mass index (BMI) ≤30 kg·m) healthy-weight (BMI <25 kg·m) subjects with asthma.
Databases including CINAHL (Cumulative Index to Nursing and Allied Health Literature), Cochrane, Embase and MEDLINE were searched up to July 2019 for English-language studies that recorded medication use or dose in obese and healthy-weight adults with asthma. A critical appraisal checklist was utilised for scrutinising methodological quality of eligible studies. Meta-analysis was performed and heterogeneity was examined with the use of the Chi-squared test. This review was conducted based on a published protocol (www.crd.york.ac.uk/PROSPERO CRD42020148671).
Meta-analysis showed that obese subjects are more likely to use asthma medications, including short-acting β-agonists (OR 1.75, 95% CI 1.17-2.60; p=0.006, I=41%) and maintenance oral corticosteroids (OR 1.86, 95% CI 1.49-2.31; p<0.001, I=0%) compared to healthy-weight subjects. Inhaled corticosteroid (ICS) dose (µg·day) was significantly higher in obese subjects (mean difference 208.14, 95% CI 107.01-309.27; p<0.001, I=74%). Forced expiratory volume in 1 s (FEV) % predicted was significantly lower in obese subjects (mean difference -5.32%, 95% CI -6.75--3.89; p<0.001, I=42%); however, no significant differences were observed in FEV/forced vital capacity (FVC) ratio between groups.
We found that obese subjects with asthma have higher use of all included asthma medication classes and higher ICS doses than healthy-weight asthma subjects, despite lower FEV and a similar FEV/FVC %. A better understanding of the factors driving increased medication use is required to improve outcomes in this subgroup of asthmatics.
肥胖是哮喘的常见合并症,与哮喘控制较差、更频繁/严重的恶化以及对哮喘药物治疗反应降低有关。
本综述旨在比较肥胖(体重指数(BMI)≤30kg·m)和健康体重(BMI<25kg·m)哮喘患者使用所有类别的哮喘药物。
截至 2019 年 7 月,使用 CINAHL(护理与联合健康文献累积索引)、Cochrane、Embase 和 MEDLINE 数据库搜索记录肥胖和健康体重成年人使用哮喘药物或剂量的英语语言研究。使用批判性评估清单仔细审查合格研究的方法学质量。进行荟萃分析,并使用卡方检验检查异质性。本综述是根据已发表的方案(www.crd.york.ac.uk/PROSPERO CRD42020148671)进行的。
荟萃分析表明,与健康体重受试者相比,肥胖受试者更有可能使用哮喘药物,包括短效 β-激动剂(OR 1.75,95%CI 1.17-2.60;p=0.006,I=41%)和维持口服皮质类固醇(OR 1.86,95%CI 1.49-2.31;p<0.001,I=0%)。肥胖受试者的吸入皮质类固醇(ICS)剂量(μg·天)明显更高(平均差异 208.14,95%CI 107.01-309.27;p<0.001,I=74%)。肥胖受试者的 1 秒用力呼气量(FEV)%预测值明显较低(平均差异-5.32%,95%CI -6.75--3.89;p<0.001,I=42%);然而,两组之间的 FEV/FVC 比值没有观察到显著差异。
我们发现,肥胖哮喘患者使用所有包括哮喘药物类别的药物和更高剂量的 ICS 高于健康体重哮喘患者,尽管 FEV 较低,FEV/FVC%相似。需要更好地了解驱动增加药物使用的因素,以改善这组哮喘患者的结局。